Bausch + Lomb Corporation (BLCO)
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb Q2 Earnings Call Highlights
Bausch + Lomb NYSE: BLCO reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook. The company said improved product mix, productivity initiatives and lower fixed-cost intensity supported margin expansion and stronger cash generation.
Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago.
Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S.
BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.07 per share a year ago.
Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript
Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position
Caspian Capital increased its Bausch + Lomb Corporation stake by 1,349,043 shares in the fourth quarter; the estimated trade value was $21.39 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $21.61 million, reflecting both trading and price changes.
Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know
Bausch + Lomb (BLCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
